Sugi Predict

Sugi Predict / Targets / KAT7

KAT7

Histone acetyltransferase KAT7 · O95251 · KAT7 on Sugi Atlas →

7,257 patent compounds predicted against KAT7, 4,417 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL3940928 SCHEMBL3940928 0.47 13/20
SCHEMBL2628029 SCHEMBL2628029 0.36 11/20
SCHEMBL2628031 SCHEMBL2628031 0.38 10/20
SCHEMBL1782414 SCHEMBL1782414 0.43 9/20
SCHEMBL2981338 SCHEMBL2981338 0.42 9/20
SCHEMBL2981343 SCHEMBL2981343 0.42 9/20
SCHEMBL10053919 SCHEMBL10053919 0.46 8/20
SCHEMBL1478103 SCHEMBL1478103 0.40 7/20
SCHEMBL1478104 SCHEMBL1478104 0.40 7/20
SCHEMBL1478152 SCHEMBL1478152 0.40 7/20
SCHEMBL1480192 SCHEMBL1480192 0.40 7/20
SCHEMBL2633191 SCHEMBL2633191 0.39 7/20
SCHEMBL2628028 SCHEMBL2628028 0.37 7/20
SCHEMBL4857301 SCHEMBL4857301 0.47 6/20
SCHEMBL1478404 SCHEMBL1478404 0.41 6/20
SCHEMBL2628030 SCHEMBL2628030 0.36 6/20
SCHEMBL10066968 SCHEMBL10066968 0.49 5/20
SCHEMBL8064800 SCHEMBL8064800 0.43 5/20
SCHEMBL1480514 SCHEMBL1480514 0.41 5/20
SCHEMBL4345848 SCHEMBL4345848 0.42 4/20

Clinical trials — most relevant to KAT7 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients PHASE3UNKNOWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab PHASE1/PHASE2RECRUITING
IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer PHASE2UNKNOWN
5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS PHASE2COMPLETED
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study PHASE2WITHDRAWN
LBH589 Treatment for Refractory Clear Cell Renal Carcinoma PHASE2COMPLETED
Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma PHASE2COMPLETED
Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer PHASE2COMPLETED
Vorinostat in Children PHASE1/PHASE2COMPLETED
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes PHASE1/PHASE2COMPLETED
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
Research In Viral Eradication of HIV Reservoirs PHASE2COMPLETED
Enhancement of in-Vitro GC Function in Patients With COPD PHASE2COMPLETED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma PHASE1UNKNOWN
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers PHASE1COMPLETED
A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers PHASE1COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load PHASE1COMPLETED
Chemoprevention of Head and Neck Squamous Cell Carcinoma (HNSCC) With Valproic Acid EARLY_PHASE1COMPLETED
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants. nanUNKNOWN
Epigenetic Evaluation of HAT/HDAC Activity in PBMC From Patients With Clinically Isolated Syndrome nanUNKNOWN
Effect of Exercise Gene Expression and Histone Modifications in Patients With Hemiplegia nanRECRUITING
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Chi-GVM Regimen for the Treatment of R/R PTCL nanUNKNOWN
X-chromosome Inactivation, Epigenetics and the Transcriptome nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a KAT7 binder may also engage these)

ProteinNameSimilarity
Q5SVQ0 — 1.000 Q5SVQ0 →
Q810T5 — 1.000 Q810T5 →
Q7S9B6 — 1.000 Q7S9B6 →
Q6C710 — 0.999 Q6C710 →
Q4IEV4 — 0.998 Q4IEV4 →
KAT8 Histone acetyltransferase KAT8 0.997 landscape →
Q9TYU5 — 0.997 Q9TYU5 →
Q5XI06 — 0.997 Q5XI06 →
Q5TKR9 — 0.996 Q5TKR9 →
Q8WML3 — 0.996 Q8WML3 →
Q61T02 — 0.996 Q61T02 →
G5EDY0 — 0.995 G5EDY0 →
Q2UMQ5 — 0.995 Q2UMQ5 →
Q19546 — 0.995 Q19546 →
Q6CKE9 — 0.995 Q6CKE9 →
KAT6B Histone acetyltransferase KAT6B 0.995 landscape →
C8VBH4 — 0.995 C8VBH4 →
Q8CHK4 — 0.995 Q8CHK4 →
G5EGA3 — 0.995 G5EGA3 →
Q21037 — 0.995 Q21037 →
Q08BS4 — 0.994 Q08BS4 →
Q9XYB7 — 0.994 Q9XYB7 →
Q4P3S3 — 0.994 Q4P3S3 →
Q92539 — 0.994 Q92539 →
Q867X0 — 0.994 Q867X0 →
P91351 — 0.994 P91351 →
A8X0L9 — 0.994 A8X0L9 →
P30181 — 0.994 P30181 →
Q95Q98 — 0.994 Q95Q98 →
Q28Z18 — 0.994 Q28Z18 →